8 unknown. 8 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 8 |
| Phase 3 | 4 | Unknown 4 |
| Phase 1 | 1 | Unknown 1 |
Follow SARS-CoV2: new trials by email Literature Review of SARS-CoV2 trials Research Report on SARS-CoV2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 Ribavirin Capsules, Favipiravir - SARS-CoV2, COVID-19 | Phase 2 / Phase 3 | Unknown | The Scientific and Technological Research Council of Turkey | 100 | 2021-04-01 | 2021-04-02 |
| Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Ivermectin Injectable Solution, Injectable Placebo, Zinc - Coronavirus Infection, COVID | Phase 1 / Phase 2 | Unknown | Sohaib Ashraf | 180 | 2020-11-14 | 2021-02-17 |
| Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Hydroxychloroquine Only Product in Oral Dose Form - Sars-CoV2, Coronavirus Infection | Phase 2 / Phase 3 | Unknown | University of Malaga | 1930 | 2020-09-01 | 2020-09-29 |
| CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms Cannabidiol, PLACEBO - SARS-CoV2 | Phase 2 / Phase 3 | Unknown | University of Sao Paulo | 100 | 2020-07-06 | 2021-09-28 |
| Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 SARS-CoV-2 convalescent plasma treatment, Standard care - Sars-CoV2, Covid-19 | Phase 2 / Phase 3 | Unknown | Fundación Santa Fe de Bogota | 236 | 2020-07-01 | 2020-06-11 |
| Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) Ciclesonide Inhalation Aerosol - Covid-19, Pneumonia, Viral | Phase 2 | Unknown | Ola Blennow, MD, PhD | 98 | 2020-05-29 | 2022-02-02 |
| Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) Mavrilimumab, Placebo - Covid-19, Acute Respiratory Failure | Phase 2 | Unknown | Ospedale San Raffaele | 50 | 2020-05-22 | 2020-05-26 |
| NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE IgIV - Sars-CoV2 | Phase 2 | Unknown | Versailles Hospital | 35 | 2020-05-05 | 2020-05-27 |
COVID-19 (6) · Coronavirus Infections (2) · Pneumonia, Viral (2) · Respiratory Distress Syndrome (1)
Coronaviridae Infections (6) · Infections (6) · Lung Diseases (6) · Nidovirales Infections (6) · Pneumonia (6) · RNA Virus Infections (6) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · Virus Diseases (6) · Coronavirus Infections (4) · Pneumonia, Viral (4) · Respiration Disorders (1)
COVID-19 Serotherapy (1) · Cannabidiol (1) · Dosage Forms (1) · Ivermectin (1) · Ribavirin (1) · Saline Solution (1) · Standard of Care (1) · Zinc (1) · ciclesonide (1) · favipiravir (1) · mavrilimumab (1)
Fundación Santa Fe de Bogota (1) · Ola Blennow, MD, PhD (1) · Ospedale San Raffaele (1) · Sohaib Ashraf (1) · The Scientific and Technological Research Council of Turkey (1) · University of Malaga (1) · University of Sao Paulo (1) · Versailles Hospital (1)
Brazil (1) · Colombia (1) · France (1) · Italy (1) · Pakistan (1) · Sweden (1) · Turkey (Türkiye) (1)
Daniel P Andersson, MD, PhD (1) · Juan C Morilla-Herrera, PhD (1) · Lorenzo Dagna, MD (1) · Moneeb Ashraf, MBBS (1) · Muhammad Ashraf, PhD (1) · Ola Blennow, MD, PhD (1) · Shoaib Ashraf, PhD (1) · Sohaib Ashraf, MBBS (1)